Flumatinib, formally known as imatinib, can treat chronic granulocytic leukemia and should be used as prescribed. Imatinib can inhibit the proliferation of leukemia cells, used in adults (Philadelphia chromosome-positive) chronic granulocytic leukemia treatment. Imatinib adverse reactions can be seen thrombocytopenia, leukopenia, neutropenia, anemia, diarrhea, abdominal pain, vomiting, nausea, liver function abnormalities, infection, malaise, fever, arthralgia, myalgia, rash, itching, dizziness, headache and so on. This product is contraindicated in people who are allergic to the active ingredients of this product and in patients with severe hepatic or renal impairment. The use of Imatinib for the treatment of chronic granulocytic leukemia should be carried out under the supervision of a doctor.